The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial

Leukemia and Lymphoma

Volumn 47, Issue 11, 2006, Pages 2321-2330

  Taylor, P R A ^a   White, J M ^b   Prescott, R J ^b   Angus, B ^a   Galloway, M J ^c   Jackson, G H ^a   Lessells, A M ^d   Lucraft, H H ^a   Summerfield, G P ^e   Proctor, S J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c Sunderland General Infirmary   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Chlorambucil; Clinical trial; Idarubicin; Interferon; Low grade lymphoma; Prognostic index

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; CHLORAMBUCIL; DEXAMETHASONE; IDARUBICIN; ONDANSETRON;

ADD ON THERAPY; ADULT; AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER REGRESSION; CANCER RISK; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG TREATMENT FAILURE; DYSPEPSIA; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; INFECTION; INSOMNIA; LETHARGY; LUNG EMBOLISM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNITED KINGDOM;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CHLORAMBUCIL; DEXAMETHASONE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ENGLAND; FEMALE; HUMANS; IDARUBICIN; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TIME FACTORS; TREATMENT FAILURE;

EID: 33751089565     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600881256     Document Type: Article

References (25)

1. Horning, S and Rosenberg, S. (1984) The natural history of initially untreated low-grade non-Hodgkin's lymphomas N Engl J Med, 311, pp. 1471-1475.
2. Ardeshna, K and Smith, P and Norton, A and Hancock, B and Hoskin, P and Mclennan, K and on behalf of the British National Lymphoma Investigation. (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial Lancet, 362, pp. 516-522.
3. Lister, T and Cullen, M and Beard, M and Brearley, R and Whitehouse, J and Wrigley, P and (1978) Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type BMJ, 1, pp. 533-537.
4. Jones, L and Cotter, F and Lord, D and Newland, A. (1990) Phase 2 study of mitozantrone in combination with chlorambucil and prednisolone for relapsed and refractory non-Hodgkin's lymphoma Haem Onc, 8, pp. 41-45.
5. Taylor, P and Jackson, G and Galloway, M and Soukop, M and Tinegate, H and Angus, B and Proctor, S. (2000) Primary treatment of low-grade non-Hodgkin's lymphoma using an all oral anthracycline-containing regimen; chlorambucil, idarubicin, dexamethasone (CID) - a phase II study Cancer Chemother Pharmacol, 46, pp. 63-68.
6. Rohatiner, A and Radford, J and Deakin, D and Earl, H and Love, S and Price, O and Wilson, A and Lister, T. (2001) Randomised controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma Br J Cancer, 85, pp. 29-35.
7. Leonard, R and Hayward, R and Prescott, R and Wang, J. (1991) The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma Ann Oncol, 2, pp. 655-663.
8. Solal-Celigny, P and Roy, P and Colombat, P and Whire, J and Armitage, J and Arranaz-Saez, R and (2004) Follicular Lymphoma International Prognostic Index (FLIPI) Blood, 104, pp. 1258-1265.
9. Stansfeld, A and Diebold, J and Noel, H and Kapanci, Y and Rilke, F and Kelenyi, G and (1998) Updated Kiel classification for lymphomas Lancet, 49, pp. 292-293.
10. Oken, M and Creech, R and Tormey, D and Horton, J and Davies, T and McFadden, G and (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol, 5, pp. 649-655.
11. World Health Organisation. (1979) WHO handbook for reporting results of cancer treatment. Geneva: World Health Organisation.
12. Harris, N and Jaffe, E and Stein, H and Banks, P and Chan, J and Cleary, M and (1994) A revised European-American classification of lymphoid neoplasms: A proposal from The International Lymphoma Study Group Blood, 84, pp. 1361-1392.
13. Kaplan, E and Meier, P. (1958) Nonparametric estimation from incomplete observations JASA, 53, pp. 457-481.
14. Peto, R and Pike, M and Armitage, P and Breslow, N and Cox, D and Howard, S and (1977) Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II Analysis and Examples Br J Cancer, 35, pp. 1-39.
15. Cameron, D and Leonard, R and Mao, J and Prescott, R. (1993) Identification of prognostic groups in follicular lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party Leuk Lymphoma, 10, pp. 89-99.
16. (1993) A predictive model for aggressive non-Hodgkin's lymphoma on behalf of the International Non-Hodgkin's Lymphoma Prognostic Factors Project N Engl J Med, 329, pp. 987-994.
17. Lopez-Guillermo, A and Montserrat, E and Bosch, F and Escoda, L and Terol, M and Marin, P and (1994) Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma J Clin Oncol, 12, pp. 1343-1348.
18. Federico, M and Vitolo, U and Zinzani, P and Chisesi, T and Clo, V and Bellesi, G and (2000) Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi Blood, 95, pp. 783-789.
19. Nicolle, A and Proctor, S and Summerfield, G. (2004) High dose chlorambucil in the treatment of lymphoid malignancies Leuk Lymphoma, 45, pp. 271-275.
20. Bernard, T and Johnson, S and Prentice, A and Jones, L and Phillips, M and Newland, A. (1994) Mitoxantrone, Chlorambucil and Prednisolone in the treatment of non Hodgkin's lymphoma Leuk Lymphoma, 15, pp. 481-485.
21. Rohatiner, A and Gregory, W and Peterson, B and Borden, E and Solal-Seligny, P and Hagenbeek, A and (2005) Met-analysis to evaluate the role of interferon in follicular lymphoma J Clin Oncol, 23, pp. 2215-2223.
22. Marcus, R and Imrie, K and Belch, A and Cunningham, D and Flores, E and Catalano, J and (2005) CVP chemotherapy plus rituximab compared with CVP as first line treatment for advanced follicular lymphoma Blood, 105, pp. 1417-1423.
23. Hiddeman, W and Kneba, M and Dreyling, M and Schmitz, N and Lengfelder, E and Schmits, R and (2005) Frontline therapy with rituximab added to the combination of cycloposphmide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with CHOP alone: Results of a prospective randomised study of the German Low Grade Lympoma Study Group Blood, 106, pp. 3725-3732.
24. Czuczman, M and Grillo-Lopez, A and White, C and Saleh, M and Gordon, L and LoBuglio, A and (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy Clin Oncol, 17, pp. 268-276.
25. Jaeger, G and Neumeister, P and Brezinschek, R and Hofler, G and Quehenberger, F and Linkesch, W and (2002) Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: A phase II study Eur J Haem, 69, pp. 21-26.